Touch Medical Media coverage of data presented at EADV 2023:
There are currently multiple therapeutics showing promise in clinical trials for chronic urticaria including anti-IL-4 monoclonal antibodies, Bruton’s tyrosine kinase (BTK) inhibitors and anti-KIT-monoklonal antibodies.
touchDERMATOLOGY were delighted to speak with Expert Faculty member Professor Emek Kocatürk (Koç University School of Medicine, Istanbul, Turkey & Charite University Institute of Allergology) to discuss the latest advancements and investigational therapeutics in chronic urticaria medicine.
The presentation ‘Incoming treatments for Chronic Urticaria‘ (Presentation ID D2T05.3C) was presented at EADV 2023, Berlin, 11-14 October 2023 #EADVCongress.
Questions
- Could you give us a brief overview of the current guidelines for chronic urticaria management? (0:30)
- What investigational therapeutics show promise for chronic urticaria? (3:49)
Disclosures: Emek Kocatürk discloses serving on advisory boards for Novartis, and Menarini.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch.
This content was developed by Touch Medical Media and is not affiliated with the European Academy of Dermatology & Venereology (EADV) or the congress.
Filmed in coverage of the EADV Annual Meeting.
Click here for more content on urticaria & for further EADV 2023 highlights visit here.
